Metis Global Partners LLC Has $523,000 Stake in Hologic, Inc. $HOLX

Metis Global Partners LLC lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 58.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,027 shares of the medical equipment provider’s stock after selling 11,274 shares during the period. Metis Global Partners LLC’s holdings in Hologic were worth $523,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the last quarter. Edgestream Partners L.P. bought a new stake in Hologic in the first quarter worth $1,038,000. Massachusetts Financial Services Co. MA increased its position in Hologic by 11.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 49,209 shares of the medical equipment provider’s stock worth $3,040,000 after buying an additional 4,918 shares during the last quarter. Wealthfront Advisers LLC raised its holdings in Hologic by 300.7% during the first quarter. Wealthfront Advisers LLC now owns 45,083 shares of the medical equipment provider’s stock valued at $2,785,000 after buying an additional 33,833 shares in the last quarter. Finally, Larson Financial Group LLC lifted its position in shares of Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 722 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $74.56 on Thursday. The firm’s 50-day moving average is $69.46 and its 200-day moving average is $65.51. The company has a market cap of $16.58 billion, a price-to-earnings ratio of 30.94, a PEG ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $80.31.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.01 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of analyst reports. UBS Group increased their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday, October 22nd. Leerink Partners increased their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, Stephens downgraded shares of Hologic from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $78.00 to $76.00 in a report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.77.

Insider Activity

In other news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.